Drug
Rgh 202
Rgh 202: highest development phase Phase 2, developed by Gedeon Richter. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gedeon Richter
Trials
| Drug | Phase | Indication |
|---|---|---|
| RGH-202 NCT07931703 | Phase 2 | Social Anxiety Disorder |
Latest
No recent events.
Follow Rgh 202 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.